Kyowa Kirin Co., Ltd.

【News Alert】 1. Announcement of Consolidated Financial Results Fiscal 2024 Second Quarter 2.  Announcement regarding the restructuring of APAC region business and Change in a Specified Subsidiary 3. Notice of transition to a research organization to realize our vision toward 2030, and introduction of a voluntary retirement program *For investors and media only.   To find the latest Kyowa Kirin global news, Click https://lnkd.in/dDqeTHSm #corporate

【News alert】 Kyowa Kirin Joins the Pharmaceutical Supply Chain Initiative (PSCI)   PSCI - Pharmaceutical Supply Chain Initiative aims to achieve excellence in safety, environmental, and social outcomes across the pharmaceutical and healthcare supply chain. Kyowa Kirin will further strengthen collaboration across the supply chain and actively promote sustainable procurement with all suppliers.   Click here for details, https://lnkd.in/gHFQKz35 #sustainability #supplychain

🌞 Seasonal Greetings from Japan! 🌞 As the summer sun shines upon us in Japan, we extend our warmest wishes to all, especially those preparing for a well-deserved summer vacation. In the spirit of Japanese summer traditions, we hope you find moments of relaxation and coolness amid the heat. In Japan, summer is a time for vibrant festivals, beach outings, and the refreshing use of traditional Japanese fans, or "uchiwa." These fans, even in nowadays, often adorned with beautiful designs, are a staple in Japanese culture, providing a gentle breeze and a touch of elegance during summertime. At Kyowa Kirin, we deeply value the well-being and work-life balance of our employees and community. We encourage everyone to take this opportunity to unwind, rejuvenate, and enjoy the simple pleasures of summer. Whether you're spending time at the beach, partaking in local festivals, or simply enjoying the comfort of an uchiwa fan, may your summer be filled with joy and serenity. Stay cool and have a fantastic summer! 🌊☀️ #KyowaKirin #SummerGreetings #haveacoolsummer #JapaneseCulture

As we celebrate 40 years of partnership dedicated to making a #profoundimpact on patient lives, I can't help but be optimistic about the future. Kyowa Kirin, Inc.- U.S./ Kyowa Kirin Co., Ltd. and Amgen have accomplished so much together, but I am confident that our finest work is still ahead.

For 40 years, Amgen and Kyowa Kirin, Inc.- U.S./ Kyowa Kirin Co., Ltd. collaborated to create innovative therapies for patients across multiple disease areas. As CEOs Bob Bradway and Masashi Miyamoto gather this week, we are reminded of the power behind our shared mission to improve patient lives.

Time to Knowledge Fusion! 🌐 Orchard Therapeutics and Kyowa Kirin Unite at Tokyo Research Park Dr. Bobby Gaspar (CEO) and Dr. Fulvio MAVILIO (CSO) from Orchard Therapeutics - U.S., a new member of Kyowa Kirin, visited Tokyo Research Park in Japan. Tokyo Research Park serves as a vital hub for leading-edge biotechnology research, while Orchard Therapeutics is an innovation-driven pioneer in hematopoietic stem cell gene therapy (HSC-GT). The visit commenced with a lunch gathering, where Kyowa Kirin scientists and the team from Orchard Therapeutics engaged in lively discussions and the exchange of ideas. Despite the limited time available, the charged atmosphere sparked curiosity and excitement about potential collaborations. Following the lunch session, an inspiring presentation took place. Bobby shared the remarkable journey of Orchard Therapeutics in pioneering treatments for rare diseases, leaving a lasting impression on all in attendance. Fulvio then captivated the audience with detailed insights into their cutting-edge research in HSC-GT, further exemplifying their commitment to innovation. The day culminated with a guided lab tour. This provided valuable insights into Kyowa Kirin's cutting-edge facilities and breakthrough advancements, enhancing the understanding of the organization's capabilities. It has been nearly half a year since Orchard joined Kyowa Kirin, and we are thrilled to combine our specialties to create life-changing value. Stay tuned to learn more about our unwavering dedication to developing innovative treatments for underserved conditions, ultimately bringing smiles to people living with disease! #KKmakespeoplesmile #KyowakirinR&D #KnowledgeFusion #Innovation 

“At Kyowa Kirin, we are guided by the power of Wa – to be in harmony, to celebrate and commemorate LGBTQ+ communities. Stemming from our shared values, Wa represents the thread that binds us, empowering each of us to be our true, authentic selves.” Read more from Jeremy Morgan, a proud ally and advocate for the #LGBTQ+ community, and President of Kyowa Kirin International plc (EMEA) https://lnkd.in/gdy-CfKM #Pride2024 #KKMakingPeopleSmile 

While there has undoubtedly been progress since the first #Pride marches in the 1970s, we recognise that members of the LGBTQ+ community still face discrimination around the world. At Kyowa Kirin, we stand as allies to create visibility, understanding and acceptance.   👉 Hear from our LGBTQ+ community members and allies from across our global team. #Pride2024 #LGBTQ+ #KKMakingPeopleSmile

We are honored to receive the 2024 Individual Alliance Excellence, Long-Established Alliance award from Association of Strategic Alliance Professionals #ASAP Our historic 40-year collaboration with Amgen has produced 8 products that enabled us to reach patients across 100+ global markets. We look forward to our continued partnership made possible by innovative science and creative alliance management. Stay tuned to learn more about our commitment to making people smile by developing innovative treatments for those living with under-treated diseases.

【News Alert】 Kyowa Kirin Announces Establishing New Biologics Manufacturing Plant in Sanford, North Carolina, in the United States The new facility will manufacture innovative biologic therapies, including next-generation antibodies, for Kyowa Kirin’s planned clinical trials and future commercial use while creating more resilient and efficient supply lines that more readily withstand shifting global forces. By locating its new site in the midst of North Carolina’s robust life sciences hub, Kyowa Kirin will benefit from a thriving network of biomanufacturing resources as well as a rich pool of talent within the greater Research Triangle Park region, the largest research park in the United States. Kyowa Kirin believes the Sanford facility will round out Kyowa Kirin’s global manufacturing network and will accelerate its development and production of biologic therapies for patients. Click here for details, https://lnkd.in/g_mWyvPr